VANCOUVER, Dec. 13, 2013 /CNW/ - CRH Medical Corporation (the "Corporation") (TSX: CRH) (OTCQX: CRMMF), today announced that its board of directors has adopted an advance notice policy regarding the nomination of directors (the "Advance Notice Policy") effective December 12, 2013. The purpose of the Advance Notice Policy is to provide shareholders, directors and management of the Corporation with direction on the procedure for shareholder nomination of directors. The Advance Notice Policy is the framework by which the Corporation seeks to fix a deadline by which registered or beneficial holders of common shares of the Corporation must submit director nominations to the Corporation prior to any annual or special meeting of shareholders and sets forth the information that a shareholder must include in the notice to the Corporation for the notice to be in proper written form. No person will be eligible for election as a director of the Corporation unless nominated in accordance with the provisions of the Advance Notice Policy.
In the case of an annual meeting of shareholders, notice to the Corporation must be made not less than 30 days and not more than 65 days prior to the date of the annual meeting; provided, however, that in the event that the annual meeting is to be held on a date that is less than 50 days after the date on which the first public announcement of the date of the annual meeting was made, notice may be made not later than the close of business on the 10th day following such public announcement.
In the case of a special meeting of shareholders (which is not also an annual meeting), notice to the Corporation must be made not later than the close of business on the 15th day following the day on which the first public announcement of the date of the special meeting was made.
At the next meeting of the Corporation's shareholders, the Corporation intends to seek shareholder approval to amend the articles of the Corporation to include the provisions of the Advance Notice Policy.
About CRH Medical Corporation:
CRH Medical Corporation is North American company focused on providing physicians with innovative products for the treatment of gastrointestinal diseases. The Company's lead product, the CRH O'Regan System, is a single use, disposable, hemorrhoid treatment that is safe and highly effective in treating hemorrhoid grades I - IV. The O'Regan System is rapidly emerging as the standard of care with gastroenterologists who treat hemorrhoids. In addition to the product, CRH Medical delivers clinical, marketing and operational support directly to its partner physicians. CRH utilizes its web-based platform to connect doctors with patients as well as educating its ever increasing install base of physicians.
SOURCE: CRH Medical Corporation
For further information:
About CRH Medical Corporation, please contact:
Edward Wright, Chief Executive Officer
CRH Medical corporation
Adam Peeler, Media and Investor Relations
416.815.0700 x 225